MedPath
NMPA Approval

Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol

国药准字HJ20190063

September 2, 2024

H20190063

Drug Information

布地格福吸入气雾剂

气雾剂

每瓶120揿,每揿含布地奈德160μg、格隆铵7.2μg和富马酸福莫特罗4.8μg

化学药品

September 2, 2024

September 1, 2029

Company Information

Applicant Company

ASTRAZENECA AB

SE-151 85 Södertälje, Sweden

Manufacturing Company

224 avenue de la Dordogne, Dunkerque 59640, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

布地格福吸入气雾剂 - NMPA 批准文号 | MedPath